About Group XIIB secretory phospholipase A2-like protein
Group XIIB secretory phospholipase A2-like protein (PLA2G12B) is a protein
from Homo sapiens identified by UniProt accession
Q9BX93, 195 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | Group XIIB secretory phospholipase A2-like protein |
|---|
| UniProt accession | Q9BX93 |
|---|
| Gene | PLA2G12B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 195 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (65)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.42
- serum alanine aminotransferase measurement · score 0.33
- alkaline phosphatase measurement · score 0.29
- low density lipoprotein cholesterol measurement · score 0.24
- HMG CoA reductase inhibitor use measurement · score 0.24
- smoking behaviour measurement · score 0.20
- coronary artery disease · score 0.09
- sex hormone-binding globulin measurement · score 0.08
- hypertriglyceridemia 2 · score 0.06
- cholesterol-ester transfer protein deficiency · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BX93-F1 | alphafold | PREDICTED | 71.58 | — |
Amino-acid sequence (195 residues)
MKLASGFLVL WLSLGGGLAQ SDTSPDTEES YSDWGLRHLR GSFESVNSYF DSFLELLGGK NGVCQYRCRY GKAPMPRPGY KPQEPNGCGS YFLGLKVPES MDLGIPAMTK CCNQLDVCYD TCGANKYRCD AKFRWCLHSI CSDLKRSLGF VSKVEAACDS LVDTVFNTVW TLGCRPFMNS QRAACICAEE EKEEL
Explore Group XIIB secretory phospholipase A2-like protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets